Moreover, SETD2 inactivation enhanced mTORC1-associated gene expression in a KRAS-driven lung adenocarcinoma model in vivo, whereas mTORC1 inhibition enhanced therapeutic susceptibilities in SETD2-inactivated cancer90. Here, SETD2 is linked to lung adenocarcinoma.